Introduction
There has been a heightened interest in the West Nile virus (WNV) within the United States due to an outbreak in the New York City area in 1999 (CDC, 1999) and a relatively rapid spread across the nation (CDC, 2002) . The virus infection had never been identified within the United States prior to 1999 and is considered to be one more example of an emerging virus due to increased population densities and accessible travel (Zorpette 2000) . This continued expansion of the virus and the possible serious prognosis underscores the need to identify effective antiviral therapies that might assist the innate immune system in the clearing of the virus and diminishing serious symptoms.
In this report, the effects of interferon-alpha (IFN-α) were determined in cell culture and mouse and hamster animal models. The rationale for using IFN-α was based on its history of animal model efficacy against various RNA viruses, including encephalitis viruses (Leyssen, et al., 2003; Wintergerst et al., 1999) . IFN-α has been active in rodent models against a wide variety of viruses including herpes simplex virus (Fish et al., 1986) , some retroviruses (Sidwell et al., 1994b; Sidwell et al., 1995) , certain bunyaviruses (Sidwell et al., 1994a; Sidwell et al., 2002) , and certain alpha-togaviruses (Lukaszewski et al., 2000; Sidwell et al., 2002) . Nevertheless, some viruses appear to be more sensitive to in vivo interferon (IFN) treatment than others. For example, IFN-α B/D treatment significantly prolonged the mean survival time of mice infected with Rauscher murine leukaemia, but only weakly prolonged survival of mice infected with the related Friend murine leukaemia virus (Gangemi et al., 1989b) . Undoubtedly, IFN-α efficacy depends on the virus genotype, pathogenesis of the virus, type of IFN used, treatment schedule, and time of admin- (Agrawal 2003) . Two cell culture studies have been published to help delineate the possible efficacy of IFNs (Anderson, et al., 2002) or other antivirals (Morrey et al., 2002) against WNV. Yet many questions about prophylactic or therapeutic treatment schedules, IFN types, and dosages remain.
Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models
WNV can cause encephalitis, so the effect of IFN on brain disease is relevant. IFN-α improved the survival of hamsters infected with subacute sclerosing panencephalitis (SSPE) virus by 20% (Takahashi et al., 1998) and the results of a clinical study suggested that IFN-α, possibly in combination with ribavirin, improved SSPE symptoms (Tomoda et al., 2001) . As another example, IFN-α B/D reduced mortality by 30% in mice with herpes simplex virus-1 encephalitis (Wintergerst et al., 1999) .
IFN-α-based therapy is the only approved therapy for hepatitis C virus (HCV), a flavivirus that is distantly related to WNV (He, et al., 2002) . With the use of combination ribavirin and pegylated-IFN, successful therapy has recently been observed in as high as 56% of HCV-infected patients; however, genotype 1a and 1b are less sensitive to this combination therapy which certainly indicates that not all flavivirus may be susceptible to such treatment. Moreover, the closely-related Japanese encephalitis virus (Harinasuta et al., 1984) and another related flavivirus, dengue fever virus (Diamond et al., 2001) , were responsive to IFN-α treatment in cell culture. More recently, IFN-α 2b was determined to be efficacious in cell culture against WNV (Anderson et al., 2002) . Characteristic of nearly all of these virus-IFN studies is the observation that IFN is effective when administered before or soon after viral challenge. Therefore, it was expected that no efficacy was observed in prevention of death or severe sequelae when treating symptomatic children having Japanese encephalitis virus infection (Solomon et al., 2003) . A clinical trial with IFN-α 2b in WNV infection has been suggested that would measure symptoms, rather than mortality, as outcome measurements (Agrawal 2003) . In light of this information on IFN-α treatment, cell culture and animal model studies were performed to more directly measure the efficacy of IFN-α B/D or an IFN alfacon-1 (Infergen) on a New York crow-brain isolate of WNV.
Materials and methods

Test agents
Human hybrid IFN-α B/D was obtained either from Dr David Gangemi (Clemson University) or from Dr Johnson Lau (Ribapharm, Inc., Costa Mesa, Calif., USA). IFN-α B/D is known to have activity in mice (Brooks et al., 1999; Gangemi et al., 1989a; Gangemi et al., 1989b; Wintergerst et al., 1999) . Infergen™ (lot no. P002586 and 202725, IFN alphacon-1, Intermune, Inc., Brisbane, Calif., USA) is a second-generation cytokine that was engineered to contain the most frequently occurring amino acids among the non-allelic IFN-alpha subtypes. The activity of Infergen reported by the supplier was 1×10 9 units/mg. In cell culture systems, Infergen demonstrates increased potency when compared to naturally occurring type 1 IFNs and is a more potent inhibitor of the HCV replication in comparative clinical trials with naturally occurring type 1 IFNs (Blatt et al., 1996; Melian et al., 2001) , Infergen is active in hamsters but not mice (Fish et al., 1986) . IFN-α2b was from ScheringPlough. Ribavirin was provided by ICN Pharmaceuticals, Inc. (Costa, Mesa, Calif., USA) and 6-azauridine was obtained from Sigma Chemical Corp. Appropriate doses of Infergen and ribavirin were mixed together for the combination study in the same injection bottle and stored at 4°C during the course of the experiment.
Drugs were co-injected subcutaneously, except for imiquimod which was administered topically. Aqueous Ampligen™ (30 µg/mL; polyI-polyC(12)U, Hemispherx Biopharma, Inc., Philadelphaia, Pa., USA) was obtained from William M Mitchell (School of Medical Pathology, Vanderbilt University). Since Ampligen is an RNA-like molecule, care was used to prevent contamination with RNase by using RNase-free materials and diethylpyrocarbonate (DEPC)-treated water. Ampligen was aliquoted and frozen until use. Aldara™ (imiquimod) was obtained from a local pharmacy in topical cream at a concentration of 12.5 mg imiquimod per 250 mg package of unidentified cream. The imiquimod cream was distributed on the sheared backs of nine mice or 10 hamsters over a surface area of 2.2 cm 2 . This resulted in dosages of 1.4 and 1.3 mg/2.2 cm 2 for mice and hamsters, respectively. The doses and treatment schedules in animals were based on previously published studies for Infergen in hamsters (Fish et al., 1986) , IFN-α B/D in mice (Gangemi et al., 1989a; Gangemi et al., 1989b) , Ampligen in mice (Leyssen et al., 2003; Sidwell et al., 1994a) and package insert of imiquimod.
Viruses and animals
A New York crow-brain isolate (NY, CDC 996625, V1 D3 11/10/1999) of WNV was used. Dengue (type 2, New Guinea C strain, obtained from Dr Dennis Trent, CDC, Fort Collins, Col., USA), yellow fever (17D strain, obtained from the ATCC, Manassas, Va., USA) and WNVs were propagated in African green monkey kidney (Vero 76, ATCC CCL1587) cells using medium 199 with 5% foetal bovine serum (FBS, HyClone, Logan, UT, USA), and 0.1% NaHCO 3 . MEM with 1% FBS, 0.18% NaHCO 3 , and 50 µg/mL gentamycin (Sigma, St Louis, Mo., USA) was used to maintain cells during antiviral experiments. The viruses were titred in sub-confluent Vero 76 cells in 96-well microtitre plates. Female 4-to 5-weekold BALB/c mice (Simonsen Laboratories, Gilroy, Calif., USA or Harlan Sprague Dawley, Indianapolis, Ind., USA), and female 4-to 5-or >7-week-old Syrian golden hamsters were used. The animals were challenged subcutaneously (s.c.) with 10 4 50% cell culture infectious doses (CCID 50 ) diluted in MEM. Animals were randomly assigned to cages and fed and watered ad libitum.
Cell culture assays
The virus titres in tissues or heparinized plasma were assayed using an infectious cell culture assay (Morrey et al., 2002) where a specific volume of either tissue homogenate or plasma was added to the first tube of a series of dilution tubes. Serial dilutions were made and added to a monolayer of Vero 76 cells in 96-well microplates. Six to 7 days later cytopathic effect (CPE) was used to identify the end-point of infection (Sidwell et al., 1971) . Four replicates were used to calculate the infectious doses per mL of plasma or gram of tissue (Reed & Muench, 1938) .
Climbing assay
Hamsters were placed at the lower end of an open-top ramp (4 inches inner width, 6 inches inner height) at a 42°incline. The ramp was designed with the consultation of an experimental psychologist (Dr Carl Cheney, Utah State University). The distance traveled by the hamster in a designated period of time of 15 sec was recorded. Measurements of uninfected hamsters were taken at night and during the day, after shaking the cage to rouse the hamsters, to determine that both measurements were similar. All hamsters, including those appearing sick, had a motivation to walk up the ramp. This assay reflected disease signs, such as muscle weakness, circling, balancing and hind-limb paralysis (Chowers et al., 2001; Xiao et al., 2001) .
Prophylactic treatment 1 day or 4-6 h before viral challenge
Female BALB/c mice (4-5 weeks old) were treated 1 day before viral challenge with intraperitoneal (i.p.) Ampligen (13 mg/kg) every other day (eod) until 9 days post-viral injection (dpi), with topical imiquimod (1.4 mg/2.2 cm 2 ), qd for 7 days, or with i.p. IFN-α B/D (6.5×10 7 U/kg) (Dr. Johnson Lau, Ribapharm, Inc.), qd for 7 days. Saline was used as the vehicle treatment for Ampligen and IFN-α B/D. Ten animals were used in each WNV-infected group and the uninfected-untreated group and six animals were used in the toxicity control groups. Percent survival was calculated based on the number of animals still alive 11 dpi.
Female BALB/c mice (4-5 week-old) were also treated 4-6 h before viral challenge with i.p. Ampligen (15 or 4.8 mg/kg) every other day (eod) until 6 dpi, or with i.p. IFNa B/D (1.5×10 7 or 1.5×10 6 U/kg) (David Gangemi, Clemson University), qd ×5 days. Saline was used as the vehicle. Percent survival was calculated based on the number of animals still alive 13 dpi.
Treatment of hamsters 4-6 h before viral injection
Female hamsters (4-5 week-old) were treated beginning 4 to 6 h before viral challenge with i.p. Ampligen (10 or 3.2 mg/kg) eod until 6 dpi, or with s.c. Infergen (10 or 1 µg/kg), qd for 7 days. Saline was used for the vehicle control group. Percent survival was calculated based on the number of animals still alive 13 dpi, and weight change difference of individual animals was from 2 days before until 7 dpi. Nine hamsters were used in the highest dosage group of each therapeutic tested and in the infected saline control group. Seven hamsters were used in the lower dosage groups and in the toxicity control groups. A lower Ampligen dosage was used in hamsters (10 mg/kg) than in mice (13-15 mg/kg) to conserve compound. Mice weighed slightly different between experiments so that the calculations of dosage were slightly different between experiments using mice.
Therapeutic combination study of Infergen and ribavirin
Sub-cutaneous treatment of hamsters was started 2 days after viral challenge. Mean percent weight gain was calculated based on the difference between 3 and 7 dpi and survival was determined up to 12 dpi. All combinations of Infergen (5, 0.5, 0.05 and 0 µg/kg) and ribavirin at (75, 7.5 and 0 mg/kg) were s.c. co-injected using 10 hamsters at 7-8 weeks of age per group. The placebo-infected control group in Trial 1 used 17 animals. Uninfected toxicity controls, using three hamsters per group, included all combinations of Infergen at 5, 0.5 and 0 µg/kg with ribavirin (75 and 0 mg/kg). A replicate trial protocol (trial 2) was performed using 5 µg/kg Infergen and 75 mg/kg ribavirin. A lower starting dosage of Infergen (5 mg/kg) was used in the combination experiment than in the monotherapy Infergen experiment (10 mg/kg) because compound needed to be conserved.
Statistical evaluation
Differences among treatment groups in weight and viral titre were analysed using the t test. Standard deviations were also determined. Wilcoxon test was used to analyse survival data. Individual weights of each animal were recorded in all experiments. The identity of each individual mouse was followed through the course of the experiment except for the experiment shown in Table 3 . Therefore, statistics for weights for all data were done on the weight change of individual mice, except that in Table 3 , which was done on final weights of individual mice between groups.
Results
Prophylactic treatment
IFN-α B/D (6.5×10 7 U/kg) and Ampligen (13 mg/kg) administered i.p. beginning one day before s.c. viral challenge prevented mortality in 100% of the mice (P<0.01), whereas the survival of control mice treated with saline were 20% and 10% for IFN-α B/D and Ampligen, respectively (Table 1 ). Topically applied imiquimod was effective in preventing mortality in 70% of infected mice (P<0.01). Plasma viral titres from mice treated with either IFN-α B/D or Ampligen, collected 3 days after viral injection, correlated with drug efficacy by reducing virus titres to below the limits of detection (P<0.001), whereas the saline placebo samples had 5 logs of WNV titre (Table 1) .
In a separate experiment also using BALB/c mice, IFN-α B/D or Ampligen administered i.p. 4-6 h before viral challenge did not statistically improve survival (Table  2) , although mice treated with both doses of Ampligen (15 and 4.8 mg/kg) and the lower of the two doses of IFN-αB/D (1.5×10 6 U/kg) had slightly increased survival rates. The delay of treatment from 1 day before viral challenge to 4-6 h before viral challenge greatly diminished the efficacies of IFN-α B/D and Ampligen.
Infergen, Ampligen and imiquimod administered 4-6 h before viral challenge appeared to improve survival of 4-5 week old hamsters as compared with a saline treated controls; however, only the imiquimod survival rate of 66% was statistically different from the saline control rate of 11% (P<0.05) ( Table 3) . Hamsters gain weight at a lower rate when infected by the virus, which was a useful parameter to monitor efficacy. All treatments improved weight change compared with the saline control group (Table 3) . The weight change from animals treated with Ampligen and imiquimod were statistically different to the control. The weight change in hamsters was another parameter besides survival that substantiated the anti-WNV effect of these therapeutics.
Therapeutic treatment
To determine if IFN-α administered after viral challenge affected morbidity or mortality, 7-8 week old hamsters were given Infergen (Fish et al., 1986) beginning 2 days after WNV injection. Older hamsters were used because they have more pronounced disease signs than younger mice or hamsters (Xiao et al., 2001) . Because ribavirin is used in combination with IFN-α to treat hepatitis C virus (Lin et al., 2001 ), a combination of ribavirin was evaluated in this study. Combination treatment of Infergen and ribavirin, co-injected s.c. beginning 2 days after viral challenge, did not act synergistically to improve the survival, the ability to climb an inclined ramp, or weight change (Table 4) . Hamsters treated with only the highest dosage (5 µg/kg) of Infergen had 90% survival, whereas those hamsters treated with placebo only had 59% survival; however, the difference was not statistically significant. A second trial was performed to confirm the apparent deleterious effect of ribavirin in infected animals and to repeat Infergen monotherapy. Survival rates of 90% in Infergen-treated animals and 50% in placebo-treated animals were observed in trial 2, which was statistically significant by a only a JD Morey et al. Statistically compared with infected saline control animals treated with saline i.p., 1 day before viral challenge, eod.
qd, (once daily); eod (every other day); dpi (days post-viral injection).
slight margin. This confirmed the efficacy of Infergen treatment when initiated 2 dpi, but the effects were slight and were not repeatable with each trial. The animals treated with 5 µg/kg Infergen, in addition to the low dosage of ribavirin (7.5 mg/kg), lost less weight than the control animals (P<0.001) ( Table 4 ). Animals treated with 5 or 0.5 µg/kg Infergen, with no ribavirin, climbed up a 42°C inclined-ramp markedly better than the control animals (P<0.01). Overall, Infergen treatment improved mortality and morbidity. All groups treated with the highest dosage of ribavirin (75 mg/kg), however, had a significantly higher mortality than all other groups. Survival was much less when WNV-infected animals were treated with the highest dosage of ribavirin. This result was confirmed in trial 2 (Table 4 ). This increased mortality was not due to toxicity of ribavirin, because the uninfected-treated control animals had the same survival, weight gain and climbing ability as the uninfecteduntreated controls.
Trial 2 was a repeat of selected groups of trial 1. In trial 2, the WNV titres in the plasma, brain, kidney and spleen were assayed to determine if these parameters correlated with Infergen efficacy. WNV titres in plasma obtained at 3 dpi from Infergen-treated hamsters (<3.9 log 10 cell culture infectious units/mL) were statistically lower (P<0.01) than the titres of animals treated with saline (6.2 log 10 cell culture infectious units/mL) ( Table 5 ). Brain and kidney titres were also lower. Reduced plasma and tissue WNV titres correlated with treatment of IFN when initiated 2 dpi. 
Efficacy of interferon on West Nile virus
Discussion
Treatment with IFN-a B/D and Ampligen prevented death in WNV-infected mice when administered 1 d before viral challenge (Table 1) , but the treatment lost much of its ability to prevent death when treatment was initiated 4-6 h before viral challenge ( Table 2 ). The in vivo activity of IFN administered 1 day before viral challenge was consistent with results of earlier animal studies using Banzi virus (Singh et al., 1989) , Venezuelan equine encephalitis virus (Lukaszewski et al., 2000) and St Louis encephalitis virus (Brooks et al., 1999) . Other RNA viruses, such as Punta Toro virus, appear to be more sensitive to IFN or IFN inducer treatment. This was evidenced by a significant improvement in survival even when therapy was initiated as late as 48 h after viral inoculation, at a time when disease signs were being manifested in the animal (Sidwell et al., 1994a) . In a murine viral encephalitis model, however, the IFN activity against Modoc virus (Leyssen et al., 2003) , an encephalitisinducing flavivirus, was similar to that observed with WNV of these studies in that the protection from mortality was not as profound as with Punta Toro virus. The IFN-inducer, Ampligen (Leyssen et al., 2003; Sidwell et al., 1994a) , has also been reported to be active in reducing mortality and paralysis in mice infected with the Modoc virus (Leyssen et al., 2003) . Another IFN-inducer, polyIC:LC, was also active against an earlier isolate of WNV (Haahr 1971) . As with IFN treatment, improvement of mortality using Ampligen was markedly diminished when treatment was delayed until 4-6 h before viral challenge.
The imiadazoquinoline compound (1-(2-methylpropyl)-1 H-imidazol4,5-clionolin-4-amine) (imiquimod) is a low-molecular weight potent IFN inducer which is FDA registered for treatment of human papillomavirus infection. The compound has been evaluated extensively against herpesvirus infection in a guinea pig model (Harrison et al., 1994; Miller et al., 2002) . It induces IFN-α, β, and other endogenous interleukins. Topical administration will elicit local and systemic responses and has been considered to have antiviral, antiproliferative and antitumour activities (Hemmi et al., 2002; Syed 2001) . When imiquimod was applied topically to mice or hamsters 1 d before WNV challenge, survival was markedly improved. We considered these WNV-imiquimod results to be encouraging, especially when considering this was a topical treatment. However, treatment was administered before, and not after, viral challenge, as further work with this material is warranted. Since IFN is efficacious against some flaviviruses when administered prophylactically or very soon after viral challenge, the window of time when WNV-infected patients might be treated with this cytokine may be very short. Moreover, the argument can be made that by the time patients have sufficient symptoms to visit the clinician, the virus itself has induced endogenous IFN (Anderson et al., 2002) and the disease may follow its course irrespective of IFN treatment. The scenario is further complicated by the occurrence of WNV-induced encephalitis, since many therapeutic agents do not cross the blood-brain-barrier; thus, options for some therapies might be limited. Despite these issues, IFN-α2b has been used in non-randomized openlabel treatment for St Louis encephalitis and in an openlabel clinical study against WNV (Agrawal 2003) . Justification for IFN use might be that it is an effective treatment for some patients infected with HCV. Additionally, there are few other options at this time for treatment of WNV, except for perhaps WNV-reactive gamma globulin (Agrawal 2003) . Interferons are notably multi-factorial (He et al., 2002) and are used to treat nonviral chronic conditions such as cancer, including brain cancer (Merchant et al., 1992) . Animal models have illustrated its efficacy to treat spongiform sclerosing panencephalitis (Takahashi et al., 1998) .
Clinical studies using IFN-α or WNV-reactive gamma globulin for treatment of WNV are suggested for the future (Agrawal 2003) . In these studies, symptoms of the disease will be used as outcome measurements, but animal model studies typically use mortality and viral titres as the outcome measurements. It is conceivable that IFN could affect symptoms or disease signs in animals or human patients without significantly affecting mortality, especially when mortality in people is low (<1%). Disease signs are more obvious in older hamsters (>7 weeks) than in mice or younger hamsters (Xiao et al., 2001) . Therefore, the use of an older hamster model might have utility in monitoring disease signs for outcome measurement. For this reason, older hamsters were treated 2 days after viral challenge with Infergen (Fish et al., 1986) , alone or in combination with ribavirin. Weight change and the ability to walk up an inclined ramp were used to reflect signs of disease such as malaise, muscle weakness, paralysis, circling, somnolence or confusion (Chowers et al., 2001; Xiao et al., 2001) . Combination treatment of Infergen and ribavirin starting 2 days after viral challenge did not act synergistically to improve survival, climbing ability that reflected disease signs, or weight change (Table 5) . However, Infergen monotherapy with increasing doses up to 5 µg/kg had a dose-responsive trend for slightly improving parameters.
These results may be clinically important because treatment was initiated 2 days after viral challenge at a time when the virus infection was well established; however, future studies should also evaluate animals treated after the appearance of overt disease signs. In the case of hamsters, this is after 5 dpi. A key concern is if IFN is therapeutically beneficial when administered past the point when the virus infects the brain. At 2 dpi, virus was detected in the brain homogenate in one of five hamsters, and it was not until 6 dpi that the virus was detected in five of five hamsters (data not shown). Detection of the virus could be from vascular infection in the brain or from infection of the neurological tissues; therefore, further work is needed to identify the time in which the virus infects neurological tissues. Even though some hamsters may have detectable virus in brain homogenates at 2 dpi when treatment was initiated, in situ immunohistochemistry should be done in future studies to confirm brain infection. Moreover, the percentage of animals with infected brains should be confirmed and correlated with IFN efficacy. If IFN were efficacious in animals having such central nervous system infections, IFN treatment might be efficacious in reducing symptoms in the clinic, even if administered after the viral infection were established in the brain. Improvement of disease symptoms is a goal of human clinical trials because lingering WNV symptoms can be debilitating and markedly decrease the quality of life. However, a randomized double-blind placebo-controlled clinical trial for treating Japanese encephalitis virus-infected Vietnamese children with IFN-α2b (Solomon et al., 2003) suggests that treatment of WNVinfected patients with IFN may not be efficacious in reducing morbidity or mortality, since there was no difference in morbidity or mortality outcome between IFN-and placebo-treated children.
Hamsters treated once daily for 7 days with the highest dosage of ribavirin (75 mg/kg) beginning 2 dpi, did not have improved climbing ability or weight change as compared to the control animals; in fact a larger proportion of animals died than with the control animals or animals treated with lower doses of ribavirin or Infergen (Table 5) . At the highest dosage, ribavirin therapy increased death in WNV-infected animals. Uninfected toxicity control animals treated with this highest dosage appeared to be well tolerated, since it did not cause any significant increase in mortality, loss of weight or climbing capacity. The results of increased mortality from ribavirin treatment was confirmed in trial 2 (Table 5 ). These data suggested that combination therapy with ribavirin plus IFN-α would not be efficacious and may in fact be contraindicated. WNV-infected patients treated with ribavirin in Israel also died at a higher rate than non-treated patients (Chowers et al., 2001) , although differences in assignment of patients to treatment groups may have accounted for this observation (Agrawal 2003; Petersen et al. 2002) . Treatment of patients with ribavirin, therefore, may not be advised. It is recognized that ribavirin does not penetrate the blood-brain barrier very well due to its low lipid solubility (partitian coefficient=-2.06). Recently, the drug has failed in all antiviral studies using central nervous system infections (Sidwell 1996) .
A New York isolate of WNV belonging to lineage 1 (Lanciotti et al., 2002) was used for these studies. Since the New York outbreak was from a single origin, the data from this report would probably be prototypic of WNV isolated in the United States. It is not known, however, if lineage 2 WNV isolates would behave in the same manner. Nevertheless, the New York isolate appears to be more pathogenic (Knudsen et al., 2003) and is certainly more relevant to the American outbreak.
In conclusion, IFN-α or inducers of IFN were efficacious in reducing mortality of mice if therapy were initiated at least 1 day before viral challenge. As expected from much previous work with IFN, IFN-α was not nearly as efficacious when administered 2 days after viral challenge; however, some improvement might provide an opportunity to reduce the severity of symptoms of a potentially debilitating sequelae. Since WNV-patients have already been treated with IFN and ribavirin and future clinical trials have been suggested Haahr 1968; Petersen et al., 2002) , this first report of IFN alone or in combination with ribavirin in WNV-infected animal models might provide useful information for subsequent treatment of patients. It may suggest that combination therapy of IFN with ribavirin would not be indicated and that IFN does not have strong antiviral effects when administered therapeutically. <3.5, <3.4, <3.3 3.6, <3.3, <3.2, <3.4, <3.3, <3.3, <3.3, <3.3 6.0, 6.3, 5.7, 6.5, <4.3, <4.3, 4.7, 6.2, <4.3, 3.3, <3.3, <3.3, <3.3, 5.8, 7.0 (6.2 
